ArticleOncotarget2025

Correction: Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression.

Haolong Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.